Here, to address these issues, we designed continuous and correlative animal and cell experiments to verify the hypotheses that FPS might ameliorate renal injury-related calcium-phosphorus metabolic disorder and bone abnormality in CKD–MBD by targeting FGF23-Klotho signaling axis and its downstream pathway, compared to Calcitriol (1α,25-dihydroxyvitamin D3, CTR). This evidence concerns the gene FGF23 and calcium metabolic disease.